{"id":"NCT01992094","sponsor":"Novartis Vaccines","briefTitle":"Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and Older","officialTitle":"A Phase III, Stratified, Randomized, Double-Blind, Multicenter, NonInferiority Study to Evaluate the Safety and Immunogenicity of a Cell-based Quadrivalent Subunit Influenza Virus Vaccine and Cell-based Trivalent Subunit Influenza Virus Vaccines in Adults Ages ≥18 Years of Age","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-11","primaryCompletion":"2014-07","completion":"2014-07","firstPosted":"2013-11-25","resultsPosted":"2015-12-10","lastUpdate":"2015-12-10"},"enrollment":2680,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Influenza"],"interventions":[{"type":"BIOLOGICAL","name":"QIVc","otherNames":[]},{"type":"BIOLOGICAL","name":"TIV1c","otherNames":[]},{"type":"BIOLOGICAL","name":"TIV2c","otherNames":[]}],"arms":[{"label":"QIVc","type":"EXPERIMENTAL"},{"label":"TIV1c","type":"ACTIVE_COMPARATOR"},{"label":"TIV2c","type":"ACTIVE_COMPARATOR"}],"summary":"Evaluate safety and immunogenicity of three influenza vaccines in adults 18 years of age and above.","primaryOutcome":{"measure":"1.Geometric Mean Titres (GMT) in Subjects After Receiving One Dose of Either QIVc, TIV1c or TIV2c","timeFrame":"Three weeks post vaccination (Day 22)","effectByArm":[{"arm":"QIVc (≥18 Years)","deltaMin":60.7,"sd":null},{"arm":"TIV1c (≥18 Years)","deltaMin":59.6,"sd":null},{"arm":"TIV2c (≥18 Years)","deltaMin":null,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":40,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":52,"n":1324},"commonTop":["INJECTION SITE PAIN","FATIGUE","HEADACHE","MYALGIA","INJECTION SITE ERYTHEMA"]}}